Biotech pharma

Arpeggio Bio

Website

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With

Founded 2018Origin source ↗Checked 2026-09-15

Overview

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

Company description As recorded 2026-11-08
Biotech pharmaBusinessesEnterpriseLicensing

Founders & team

Previously Arpeggio Biosciences

Company history As recorded 2026-11-08
20team members reported
Source-reported As recorded 2026-09-15

Founded 2018 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationsite error
Last website check2026-11-11
Location · source statedBoulder, CO, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The latest website check does not confirm this company’s website.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationdescriptive evidenceclassified market and modelsourced peoplesourced founding year
startup.observe Directory coverage · Sources & method